百日咳毒素(百日咳杆菌)
- 产品特性
- 相关资料
- Q&A
- 参考文献
百日咳毒素(百日咳杆菌)
可提供优质抗原性的超纯百日咳毒素
● 更高的特异性和敏感性
● 产品间批次差异小
● 可重复批量放大
● 延长保质期的冻干形式
◆产品规格
别名:胰岛激活蛋白,PTX,全毒素
来源:百日咳博德特氏菌,菌株165。
CAS:70323-44-3
配方:冻干。含有磷酸钠和氯化钠。
纯度:≥99%
纯度细节:
在12%聚丙烯酰胺SDS-尿素凝胶上运行时,该产品以5个不同的条带迁移。五个条带由一个A原子亚基(S1,MW=26.2 kDa)和四个B寡聚体亚基(S2,S3,2x S4,S5;MW's:21.9,21.9,12.1,10.9 kDa)组成。
运输:室温
长期储存:+ 4°C
使用/稳定性:
将该制剂冻干,无菌包装并真空密封。不要旋涡。在重组前和之后储存于4°C。不要冻结。这种毒素被认为具有生物活性。冻干制剂将保持活性至少一年。用无菌水复溶后,如果在4℃下储存,该产品应保持活性至少6个月。每个小瓶在用无菌蒸馏水复溶为500 μL时,pH 7.0下,在50 mM氯化钠、10 mM磷酸钠缓冲液中含有50 μg百日咳毒素。毒素具有不溶性,所得到的悬浮液应在取出等分试样之前通过温和混合而不是涡旋进行匀液。不要无菌过滤。为了与纯化的G蛋白一起使用,毒素必须在结构上被转化成人为产生与G蛋白直接相互作用的毒素形式。
参见Kaslow等(1987)
本产品只能由技术人员使用。应采用良好的实验室设备:切勿口腔吸移;戴手套、穿着防护服;避免吸入;避免与皮肤接触或开放伤口;用肥皂和水彻底清洗与毒素接触的身体任何区域;用水洗眼十五分钟;运动护理在皮下注射针头处理以避免无意中的静脉或皮下注射。
处理:
无菌包装,真空密封。不要旋涡,不要冻结。
科学背景:
百日咳毒素由具有NAD +糖水解酶和ADP-核糖基转移酶活性的酶活性A原子亚基(S-1)和B寡聚体亚基(S-2,S-3,S-4和S-5)组成),其负责将天然毒素附着到真核细胞表面。百日咳毒素通过ADP核糖基化A亚基的羧基末端附近的半胱氨酸将来自受体的G蛋白解偶联。
参考文献
[1] |
Comprehensive analysis of chemokine-induced cAMP-inhibitory responses using a real-time luminescent biosensor: V. Felouzis, et al.; Cell. Signal. 28, 120 (2016), Application(s): Cell culture , Abstract; |
[3] |
In vivo immunomodulatory effects of adipose-derived mesenchymal stem cells conditioned medium in experimental autoimmune encephalomyelitis: F. Yousefi, et al.; Immunol. Lett. 172, 94 (2016),Application(s): Injection into mice, Abstract; |
[4] |
Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice: Y. Sun, et al.; J. Neuroimmunol. 292, 58 (2016), Application(s):Injected into mice, Abstract; Full Text |
[5] |
Treatment with NAD+ inhibited experimental autoimmune encephalomyelitis by activating AMPK/SIRT1 signaling pathway and modulating Th1/Th17 immune responses in mice: J. Wang, et al.; Int. Immunopharmacol. 39, 287 (2016), Application(s): Experimental autoimmune encephalomyelitis (EAE) induction, mice, Abstract; |
[6] |
GABAB receptors inhibit low-voltage activated and high-voltage activated Ca2+ channels in sensory neurons via distinct mechanisms: D. Huang, et al.; Biochem. Biophys. Res. Commun. 465, 188 (2015), Application(s):LVA and HVA channel inhibition , Abstract; |
[7] |
Protective effect of a novel Rho kinase inhibitor WAR-5 in experimental autoimmune encephalomyelitis by modulating inflammatory response and neurotrophic factors: Y.H. Li, et al.; Exp. Mol. Pathol. 99, 220 (2015),Application(s): Injection into mouse abdominal cavity, Abstract; |
[8] |
Amidate prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine as inhibitors of adenylate cyclase toxin from Bordetella pertussis: M. Šmídková, et al.; Antimicrob. Agents Chemother. 58, 664 (2014), Application(s): Cell Culture, Abstract; Full Text |
[9] |
Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice: S. Bittner, et al.; J. Vis. Exp. 86, e51275 (2014), Application(s): Immunization,Abstract; Full Text |
[10] |
The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice: S. Fakharzadeh, et al.; Int. J. Nanomedicine 9, 3841 (2014),Application(s): Immunization, Abstract; Full Text |
[11] |
Human apolipoprotein AI induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1: D. Liu, et al.; Am. J. Physiol. Cell Physiol. 301, C739 (2011), Application(s): Treatment of HUVEC, Abstract; Full Text |
[12] |
A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit: C. Locht& R. Antoine; Biochimie 77, 333 (1995), Abstract; |
[13] |
Pertussis toxin and target eukaryotic cells: binding, entry, and activation: H.R. Kaslow& D.L. Burns; FASEB J.6, 2684 (1992), Abstract; |
[14] |
Structure-activity analysis of the activation of pertussis toxin: H.R. Kaslow et al.; Biochemistry 26, 123 (1987),Abstract; |
[15] |
Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin: E.L. Hewlett et al.; Infect. Immun. 40, 1198 (1983), Abstract; |
[16] |
Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model: M. Tamura et al.; Biochemistry 21, 5516 (1982), Abstract; |
产品编号 | 产品名称 | 产品规格 | 产品等级 | 备注 |
BML-G100-0050 | 百日咳毒素(百日咳杆菌) Pertussis toxin (Bordetella pertussis) |
50 μg |